MY174681A - Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid - Google Patents

Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Info

Publication number
MY174681A
MY174681A MYPI2010000053A MYPI2010000053A MY174681A MY 174681 A MY174681 A MY 174681A MY PI2010000053 A MYPI2010000053 A MY PI2010000053A MY PI2010000053 A MYPI2010000053 A MY PI2010000053A MY 174681 A MY174681 A MY 174681A
Authority
MY
Malaysia
Prior art keywords
phenyl
amino
imidazol
propionyl
carbamoyl
Prior art date
Application number
MYPI2010000053A
Inventor
Anzalone Luigi
Feibush Penina
J Villani Frank
Allan Teleha Christopher
Fegely Barry
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY174681(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MY174681A publication Critical patent/MY174681A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

The present invention relates to a novel crystals of 5-( { [2-amino-3-( 4-carbamoyl-2,6- dimethyl-phenyl)-propionyl]-[ 1-( 4-phenyl-1 h-imidazol-2-yl)-ethyl]-amino }-methyl)-2- methoxy-benzoic acid and methods of making the zwitterion of 5-( { [2-amino-3-( 4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[ 1-( 4-phenyl-l h-imidazol-2-yl)-ethyl]-amino }-methyl)-2-methoxy-benzoic acid.
MYPI2010000053A 2007-07-09 2008-07-07 Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid MY174681A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94858407P 2007-07-09 2007-07-09

Publications (1)

Publication Number Publication Date
MY174681A true MY174681A (en) 2020-05-07

Family

ID=39926468

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010000053A MY174681A (en) 2007-07-09 2008-07-07 Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Country Status (25)

Country Link
US (7) US7994206B2 (en)
EP (1) EP2176234B1 (en)
JP (5) JP5702140B2 (en)
KR (2) KR101690161B1 (en)
CN (3) CN111620823A (en)
AU (1) AU2008275270C1 (en)
BR (1) BRPI0813632A2 (en)
CA (1) CA2695126C (en)
CO (1) CO6260079A2 (en)
CR (1) CR11260A (en)
EA (1) EA020024B1 (en)
EC (1) ECSP109863A (en)
ES (1) ES2567077T3 (en)
HK (1) HK1141519A1 (en)
HU (2) HUE028538T2 (en)
IL (1) IL203081A (en)
MX (1) MX339569B (en)
MY (1) MY174681A (en)
NI (1) NI201000001A (en)
NZ (1) NZ582420A (en)
PH (1) PH12016502561A1 (en)
SG (1) SG185941A1 (en)
UA (1) UA104713C2 (en)
WO (1) WO2009009480A2 (en)
ZA (1) ZA201000921B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7412462B2 (en) 2000-02-18 2008-08-12 Burnside Acquisition, Llc Data repository and method for promoting network storage of data
SG185941A1 (en) 2007-07-09 2012-12-28 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline
WO2017114446A1 (en) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 New crystal form of eluxadoline and preparation method thereof
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
US20190177281A1 (en) * 2016-05-03 2019-06-13 Sromovasam THIRUMALAI RAJAN Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (en) 2016-09-07 2018-03-14 Zentiva, K.S. Solid state forms of eluxadoline
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
EP3515434A4 (en) * 2016-09-20 2020-02-26 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018069770A1 (en) * 2016-10-14 2018-04-19 Allergan Holdings Unlimited Company Methods of treatment using eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
WO2018138274A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline forms and processes for their preparation
WO2018198101A2 (en) * 2017-04-25 2018-11-01 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline form of eluxadoline
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited Novel forms of mu-opioid receptor agonist
CA3018321A1 (en) 2017-09-25 2019-03-25 Apotex Inc. Novel crystalline form of eluxadoline
US10298921B1 (en) * 2018-02-27 2019-05-21 Looking Glass Factory, Inc. Superstereoscopic display with enhanced off-angle separation
US20210251964A1 (en) 2018-08-20 2021-08-19 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
US20230118152A1 (en) * 2020-03-30 2023-04-20 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003065441A (en) 2001-08-28 2003-03-05 Japan Matekkusu Kk Packing material and gland packing using this material
PT2573068E (en) 2004-03-15 2015-04-27 Janssen Pharmaceutica Nv Process for preparing intermediates of compounds useful as opioid receptor modulators
JP2008533141A (en) 2005-03-14 2008-08-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Method for producing opioid modulator
SG185941A1 (en) 2007-07-09 2012-12-28 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid

Also Published As

Publication number Publication date
JP5702140B2 (en) 2015-04-15
CO6260079A2 (en) 2011-03-22
AU2008275270A1 (en) 2009-01-15
EP2176234A2 (en) 2010-04-21
CA2695126A1 (en) 2009-01-15
KR20150080006A (en) 2015-07-08
ES2567077T3 (en) 2016-04-19
ZA201000921B (en) 2011-04-28
JP5852625B2 (en) 2016-02-03
IL203081A (en) 2016-09-29
EP2176234B1 (en) 2016-01-27
UA104713C2 (en) 2014-03-11
PH12016502561A1 (en) 2017-09-04
JP6321690B2 (en) 2018-05-09
HUS1700011I1 (en) 2017-04-28
KR20100043210A (en) 2010-04-28
EA201070116A1 (en) 2010-06-30
BRPI0813632A2 (en) 2014-12-23
US20160354389A1 (en) 2016-12-08
US9115091B2 (en) 2015-08-25
EA020024B1 (en) 2014-08-29
JP2014144946A (en) 2014-08-14
HUE028538T2 (en) 2016-12-28
AU2008275270B2 (en) 2013-10-10
WO2009009480A3 (en) 2009-03-12
US20110263868A1 (en) 2011-10-27
CA2695126C (en) 2018-10-30
US8859604B2 (en) 2014-10-14
HK1141519A1 (en) 2010-11-12
JP5870220B2 (en) 2016-02-24
US8609865B2 (en) 2013-12-17
NI201000001A (en) 2010-07-22
JP2016128433A (en) 2016-07-14
KR101590596B1 (en) 2016-02-01
WO2009009480A2 (en) 2009-01-15
JP2010533191A (en) 2010-10-21
SG185941A1 (en) 2012-12-28
US20150099724A1 (en) 2015-04-09
US8691860B2 (en) 2014-04-08
CN101730685A (en) 2010-06-09
JP2018123144A (en) 2018-08-09
US9364489B2 (en) 2016-06-14
MX339569B (en) 2016-05-31
US20090018179A1 (en) 2009-01-15
KR101690161B1 (en) 2016-12-27
US20160015724A1 (en) 2016-01-21
AU2008275270C1 (en) 2014-04-17
CR11260A (en) 2013-01-25
JP2015129154A (en) 2015-07-16
US7994206B2 (en) 2011-08-09
CN111620823A (en) 2020-09-04
US20140221444A1 (en) 2014-08-07
US20140011851A1 (en) 2014-01-09
CN105111149A (en) 2015-12-02
US9789125B2 (en) 2017-10-17
ECSP109863A (en) 2010-02-26
NZ582420A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
MY174681A (en) Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
CR20110260A (en) PHARMACEUTICAL DOSAGE FORM INCLUDING NIFEDIPINO OR NISOLDIPINO AND AN ANTAGONIST OF ANGIOTENSIN II AND / OR A DIURÉTIC
EA201071151A1 (en) Intrathecal system
MA32977B1 (en) Polymorphic of (s) -3-aminomethyl-7-(3-hydroxy-propoxy) -3h-benzo (c (1,2) oxporol-1-ol
NZ626505A (en) Substituted pyrrolidine-2-carboxamides
ZA201004848B (en) Method for the production of disubstituted imidazolium salts
CL2007002949A1 (en) CRYSTAL FORM OF THE COMPOUND 2-CHLORINE-5- (3,6-DIHIDRO-3-METHYL-2,6-DIOXO-4- (TRIFLUOROMETIL) -1- (2H) -PIRIMIDINIL) -4-FLUORO-N - (( METHYL (1-METHYLETY) AMINO) SULFONILE) BENZAMIDE; PROCESS FOR THE PREPARATION OF SUCH CRYSTAL FORM; PHYTOPROTECTOR COMPOSITION;
WO2009064920A3 (en) Compounds and methods for modulating protein expression
HUE052128T2 (en) Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
MA32255B1 (en) Process for the preparation of triamides from ammonia and amidodichlorides
MY171361A (en) Method for producing a methionine salt
UA113391C2 (en) Asparaginase from basidiomycetes
PL2225238T3 (en) Derivatives of 6,7-dihydro-5h-imidazoý1,2- ¨imidazole-3- carboxylic acid amides
EP2022852A4 (en) Method for production of optically active amine compound, recombinant vector, and transformant carrying the vector
AP2010005262A0 (en) Improved method for the production of hydrocyanic acid by catalytic dehydration of gaseous formamide
EP2213656A4 (en) Process for production of cyanohydrin compound, and process for production of alpha-hydroxyester compound
MX2010009931A (en) Process for the preparation of 2-amino-2- [2- (4-c3-c21-alkyl-phenyl)ethyl] propane-1, 3-diols.
EP2226317A4 (en) Aryl (1h-1,2,4-triazol-1-yl) compound, and process for production thereof
AU2014220865A8 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
EA201190256A1 (en) A METHOD FOR REDUCING THE LEVEL OF UBIVITILATED PROTEINS
PL382346A1 (en) The manner of production of salt of 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-ethenylo)phenylo)-3-(2-(1-hydroxy-1- methyloethylo)phenylo)propylo)sulphanylo)methylo)-cyclopropaiacetic acid
MY177115A (en) Process for the enzymatic synthesis of (7s)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) n-methyl methanamine, and application in the synthesis of ivabradine and salts thereof
CL2011000297A1 (en) Ivabradine synthesis procedure using a hemitioacetal intermediate; and the intermediary compounds considered.
MX2013011151A (en) Process for the preparation of 1 - ( 2 -methyl - 4 - ( 2, 3, 4, 5 - tetrahydro - 1 - benzazepin- 1 -ylcarbonyl) benzylcarbamoyl) - l - proline - n, n- dimethylamide.
PL393842A1 (en) New coordinating compound of [diiodo(tris(1-(3,5-dimethylpyrazole)-methyl)amine)cadmium(II) and method of its manufacturing